ArticleJournal of veterinary internal medicine2021
Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
Article in Journal of veterinary internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 65 citations in OpenAlex.
- Case Report: Severe wound formation following intratumoral tigilanol tiglate treatment resulting in limb amputation in a 10-year-old male dog.Frontiers in veterinary science · 2026Article
- Proof of concept for low dose and delayed release of tigilanol tiglate in the treatment of equine sarcoids.Frontiers in veterinary science · 2026Article
- Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.Equine veterinary journal · 2026Article
- Article
- Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.Journal for immunotherapy of cancer · 2024Article
- Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors.Frontiers in immunology · 2024Review
- Tigliane Diterpenoids.Progress in the chemistry of organic natural products · 2024Review
- Anal sac mast cell tumor in a dog.The Canadian veterinary journal = La revue veterinaire canadienne · 2023Article
- Tumor microenvironment signaling and therapeutics in cancer progression.Cancer communications (London, England) · 2023Review
- Evidence for Natural Products as Alternative Wound-Healing Therapies.Biomolecules · 2023Review
- Development of a flow cytometric panel to assess prognostic biomarkers in fine needle aspirates of canine cutaneous or subcutaneous mast cell tumors.Frontiers in veterinary science · 2023Article
- Identification of Gene Biomarkers for Tigilanol Tiglate Content inMolecules (Basel, Switzerland) · 2022Article
- Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.Cells · 2022Review
- Malignancy prediction of cutaneous and subcutaneous neoplasms in canines using B-mode ultrasonography, Doppler, and ARFI elastography.BMC veterinary research · 2022Article
- Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.Frontiers in veterinary science · 2022Article
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nature reviews. Clinical oncology · 2021Review
- Developing a Nicotiana benthamiana transgenic platform for high-value diterpene production and candidate gene evaluation.Plant biotechnology journal · 2021Article
- Floral attraction and flower visitors of a subcanopy, tropical rainforest tree,Ecology and evolution · 2021Article
- The P450 multigene family of Fontainea and insights into diterpenoid synthesis.BMC plant biology · 2021Article
- Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 3 countries.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of tigilanol tiglate (TT) for local intratumoral treatment of mast cell tumors (MCTs) in dogs.
methodsA randomized controlled clinical study in 2 phases involving 123 dogs with cytologically diagnosed MCT. Phase 1 compared 81 TT-treated dogs with 42 control dogs; phase 2 allowed TT treatment of control dogs and retreatment of dogs that failed to achieve tumor resolution after TT treatment in phase 1. Tigilanol tiglate (1 mg/mL) was injected intratumorally with dose based on tumor volume. Concomitant medications were used to minimize potential for MCT degranulation. Modified response evaluation criteria in solid tumors were used to evaluate treatment response at 28 and 84 days. Adverse events and quality of life were also assessed.
resultsA single TT treatment resulted in 75% complete response (CR) (95% confidence interval [CI] = 61-86) by 28 days, with no recurrence in 93% (95% CI = 82-97) of dogs by 84 days. Eight TT-treated dogs that did not achieve CR in phase 1 achieved CR after retreatment, increasing the overall CR to 88% (95% CI = 77-93). Control dogs had 5% CR (95% CI = 1-17) at 28 days. Wound formation after tumor slough and wound size relative to tumor volume were strongly associated with efficacy. Adverse events typically were low grade, transient, and directly associated with TT's mode of action.
conclusionsTigilanol tiglate is efficacious and well tolerated, providing a new option for the local treatment of MCTs in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.